Peripheral targeting of TNFR1 and Lcn2 as treatments for Alzheimer’s disease

We recently found that intraperitoneal application of the TNF receptor 2 agonist: Star 2 (1), improved spatial learning and abrogated Amyloid plaque formation in a J20 Alzheimer mouse model (1) (see figure 1). We want to test the hypothesis whether systemically blocking TNFR1 and Lcn2 can also improve AD related cognitive dysfunction and pathology.